名称 | Abeprazan hydrochloride |
描述 | Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers. |
体外活性 | The mechanism of action of Abeprazan hydrochloride involves reversible binding to H+, K+-ATPase, and, unlike PPIs, it does not require an acidic environment for activation [1]. |
体内活性 | Abeprazan hydrochloride effectively suppresses acid secretion in a dose-responsive manner, demonstrating equal or superior efficacy to vonoprazan, an established P-CAB, across multiple in vivo studies including pylorus-ligated rats, lumen-perfused rat models, and Heidenhain pouch dog models[1]. |
存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 40 mg/mL (89.51 mM), Sonication is recommended.
|
关键字 | Fexuprazan Hydrochloride | Abeprazan Hydrochloride | DWP-14012 Hydrochloride | DWP 14012 Hydrochloride | DWP14012 Hydrochloride |
相关产品 | Ilaprazole | Esomeprazole | Abscisic Acid | Esomeprazole Magnesium | Pantoprazole Sodium Hydrate | Vonoprazan Fumarate | Lansoprazole | Zinc pyrithione | Esomeprazole Sodium | Pantoprazole |
相关库 | 外泌体相关化合物库 | 经典已知活性库 | 膜蛋白靶向化合物库 | 药物功能重定位化合物库 | 抑制剂库 | 线粒体靶向库 | 临床期小分子药物库 | 已知活性化合物库 |